National ART Program - NAP Utilization of NAP Monitoring data for Policy Decision “Treatment as Prevention” Sorakij Bhakeecheep, MD Director National Health.

Slides:



Advertisements
Similar presentations
Priority Issues and Strategic Information Needs for Kenya in scaling up ART.
Advertisements

Scaling up ART in Sénégal: specifics needs for strategic information Mame Awa Toure MD, MSc AIDS/STI Division, MOH Senegal.
Stigma Research and Prevention Taweesap Siraprapasiri, MD National AIDS Management Center Disease Control Department Ministry of Public Health Evidence.
Follow-up after training and supportive supervision The IMAI District Coordinator Course.
Antiretroviral therapy eligibility at enrollment and time to treatment initiation in Ethiopia Chloe A. Teasdale 1, Chunhui Wang 1, Sileshi Lulseged 1,
Urgent need to strengthen active tracing of lost to follow up cases: a prospective cohort study of newly diagnosed HIV clients in rural districts, Zambia.
Utilizing Facility Data for Program Monitoring Valerie Koscelnik Track 1 ART Program Meeting Maputo, August 12, 2010.
Thailand’s HIV and AIDS STRATEGY
User Perspective on ARV-Based HIV Prevention Suwat Chariyalertsak, MD., Dr.PH Research Institute for Health Sciences Chiang Mai University.
ART in Resource-limited settings : Progress and Challenges Dr. B. B. Rewari MD,FRCP,FICP,FIACM,FGSI,FIAMS,FIMSA, NPO (ART) India 21 st July 2014, Adult.
Fast-track to ending AIDS in Zimbabwe: opportunities
The Implementation of the WHO Asia Pacific Treatment Metrics Dr. YU, Dongbao WHO Regional Office for the Western Pacific 20 July, 2014 Antiretroviral Treatment.
“Getting to Zero: Thailand’s Experience with E-MTCT” Petchsri Sirinirund Advisor on HIV/AIDS Policy and Programme Department of Disease Control, Thailand.
Integrating TB into PWID Services in Indonesia The Works in Progress Dr Siti Nadia, NAP Manager; Dr Dyah Erti Mustikawati, NTP Manager Melbourne AIDS Conference.
Kevin Fenton, MD, PhD, FFPH Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Centers for Disease Control and Prevention.
Creating an AIDS-Free Generation The beginning of the end of AIDS Center for Strategic & International Studies Washington, DC March 22, 2012 Thomas R.
Current status, problems, and challenges in public health in Thailand Dr. Phusit Prakongsai, MD. Ph.D. International Health Policy Program – IHPP Ministry.
Ilesh V. Jani, MD PhD Instituto Nacional de Saúde Maputo, Mozambique.
Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.
Downloaded from Accelerate scaling up of TB/HIV activities in Tanzania Dr. N.G.SIMKOKO WHO/NTLP - Tanzania.
Group Discussion Guyana, The Bahamas T & T, Jamaica Barbados, Haiti Suriname, Curacao.
Expert Consultation on Costing HIV Responses in Asia - Pacific October 2010 Recap of Day 1.
Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Sombat Thanprasertsuk MD, MPH Department of Disease Control, MOPH Thailand 2 July 2013.
The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.
Nomsa Mulima 17 th July 2011 Effectiveness of the PMTCT program in Swaziland.
1 HIV/AIDS Related Research Agenda Workshop Phnom Penh, Sunway Hotel March 28-29, 2007.
Components of HIV/AIDS Case Surveillance: Case Report Forms and Sources.
6 th Biannual Joint HIV Sector Review Meeting Nov 11-13,2014 Ministry of Health and Social Welfare Mwanaisha Nyamkara, NTLP Werner Maokola, NACP Nov 11,
Orientation on HIV care and ART Recording and Reporting System.
NURSETRI, Nursing role in HIV care : an overview Jane Bruton Clinical Research Nurse.
Improving access to care and treatment services for children affected by HIV/AIDS in Andhra Pradesh, India Ajay Kumar Reddy Technical Manager – Monitoring.
Downloaded from Current Status of ART Opportunities & Challenges Kibrebeal Melaku,MD Associate Professor.
Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.
Prevention with Positives: view from health provider Sakchai Chaiyamahapurk* Supasit Pannarunothai** Office of Disease Control and Prevention 9 th Phitsanulok*
‘Gaps in the global HIV/AIDS success story Copenhagen December 2 nd 2013 Gaps in the global HIV/AIDS success story Briefing on HIV/AIDS in Europe Martin.
Understanding temporal trends in HIV prevalence, incidence and ARV Dr Valerie Delpech Head of HIV surveillance Public Health England.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.
Sub module 1 Introduction to HIV care and ART recording and reporting system.
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
Efficiency, Effectiveness, and Financial Sustainability: The Importance of Country Ownership Dr Bernhard Schwartländer UNAIDS.
HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.
Getting more value for money: working with countries and partners toward greater effectiveness and efficiency Peter Stegman, Senior Economist.
Antiretroviral treatment programme in Thyolo district, Malawi Southern Region. MSF Luxembourg & Thyolo District Health Services - Strategic information.
STRATEGIC INFORMATION FOR ACTION IN VIET NAM 6 th Viet Nam National Scientific Conference 24 November 2015 Ha Noi, Viet Nam Amitabh Bipin SUTHAR, PharmD,
HHS/CDC Track 1.0 Transition in Rwanda Dr Ida Kankindi, Rwanda Ministry of Health Dr Felix Kayigamba, CDC-Rwanda August
United Republic of Tanzania Ministry of Health & Social Welfare MINISTRY OF HEALTH AND SOCIAL WELFARE NATIONAL AIDS CONTROL PROGRAM HIV CARE AND TREATMENT.
ARV Treatment Scale Up: Progress in Ukraine Andriy Klepikov Executive Director, International HIV/AIDS Alliance in Ukraine ARV Treatment Scale Up: Progress.
Successfully enrolled in HIV Care but not linked to timely Treatment: Poor retention and Monitoring of Pre-ART patients who are not yet eligible for ART.
Prevention of Mother-to-Child Transmission of HIV: Scale-up of Critical Services in Uganda (District- based Approach) Edward Bitarakwate, MD, MPH Technical.
Evidence-based strategic investment to sustain the HIV response Conference on Measuring and Achieving Universal Health Coverage (UHC) with Information.
From Aggregate Indicators to Impacting Patients - Data Use to Inform Treatment and Improve Care Ian Wanyeki Track 1.0 Implementers Meeting Dar Es Salaam.
Expert Patients and AIDS Ministry of HealthMSF-OCB Mozambique CDC From Field Operational Research to National Roll Out of CASG in Mozambique.
Moving from a commodity approach: “Fund some of everything” or “Fund what is comfortable” to An Investment approach: “Fund evidenced-based activities.
Boston University Slideshow Title Goes Here Eliminating CD4 thresholds in South Africa will not lead to large increases in persons receiving ART without.
Thailand experience in implementing collaborative HIV/TB activities Anupong Chitwarakorn, MD Ministry of Public Health, Thailand TB/HIV Satellite symposium.
Treatment as prevention: policy and programmatic considerations
New WHO Guidelines on Person centred monitoring
Differentiated Monitoring & Evaluation
Durban, July 20th 2016 Ruggero Giuliani MSF - Mozambique
Thailand’s HIV and AIDS STRATEGY
Peeramon Ningsanond MD. Bureau of AIDS TB STI, DDC, MOPH Thailand
Current harm reduction program at outreach
USAID SHIFT YEAR1 Technical Strategies and Priority TA
Countries in transition – The challenges of middle-income countries 18 July 2016 AIDS 2016 in Durban, South Africa Sumet Ongwandee, MD MS MPH Bureau of.
Implementation of the Appointment Spacing Model of Differentiated Service Delivery in Ethiopia: Successes and Challenges Tamrat Assefa1, Zenebe Melaku1,
HIV Quality Improvement (QI) and the Treatment Cascade: How QI has Impacted Reach, Recruitment, Testing, Treatment, and Retention Efforts in Thailand?
Petchsri Sirinirund Advisor to HIV/AIDS Policy and Programme
Sustaining Primary Care-Public Health Partnerships for Engagement in Care – The Partnerships for Care Demonstration Project Sue Lin, PhD, MS Director,
Multi-disease diagnostic integration
A pathway to policy commitment for sustainability of a key population-led health services model in Thailand Dr. Preecha Prempree Deputy Director-General,
Presentation transcript:

National ART Program - NAP Utilization of NAP Monitoring data for Policy Decision “Treatment as Prevention” Sorakij Bhakeecheep, MD Director National Health Security Office, Region 1 THAILAND.

Contents Brief overview ART program Thailand National patient monitoring system - NAP Utilization of NAP monitoring data for policy decision “Treatment as Prevention”

ART Program in Thailand ARV research (mono/dual) National Access to ARV Treatment for PLHIV (NAPHA) (Pilot program under GF and MoPH research fund) PMTCT researches National Health Security Act (Health promotion, Prevention, Cure and Rehabilitation) PMTCT National Program 14 ART at CD4<350 Advocate TasP (Any CD4) Universal Access to ART ART at CD4<200

ART Coverage among Persons Living with HIV Number of PLHA Receiving ART ( ) PLHA-CD4 ≤ 500 Source: AIDS Epidemic Model (AEM), NHSO – NAP, SSO, CSMBS, GF, and Thai GPO PLHA-≤ ,049 Area graph shows estimated persons living with HIV by CD4 levels Linear graph shows number of currently PWHA retain in the cohort The coverage is 80% according to CD4<350 80% Coverage of ART need (CD4<350)

National AIDS Program Monitoring System (NAP) -Implemented in April Designed for supporting patient care, fund administration and program monitoring -Web application architecture -Centralized user management system -Individual data collecting with transaction oriented (medications, lab, etc) -National ID encryption to avoid data duplication

Overview of NAP System Architecture Health Service ProvidersNational Health Security Office VCT facilities HIV clinics Laboratories Procurement & Logistics Link to Birth-Death Registration from ministry of interior AIDS experts Internet Data Processing NAP Database Internet Fund Administration Program Monitoring Policy decision & planning Patient monitoring and quality improvement

Concept of Using Data to Inform Policy Information base Policy Analysis Policy Decision Resource Preparation Knowledge base InputProcessOutput

Evidence Based of Treatment as Prevention: Clinical vs. Public Health Aspect Currently, there is insufficient evidence and/or favorable risk-benefit profile to support initiating ART at CD4 >500 or regardless of CD4 …. (Clinical aspect) (Reference: WHO Consolidated Guidelines on The Use of ARV Drugs for Treating and Preventing HIV Infection : p. 93) Observation from HTPN 052 :- PWHA receiving ART with suppressed viral load would reduce risk of HIV transmission to their partners (Prevention aspect) In conclusion, the benefits of starting ART at CD4 >500 is not for who’s taking ARV drugs, but for their partners (Public Health Benefit)

What should be considered in addition to efficacy and benefit of an intervention? 1.Cost-effectiveness (Return of investment) 2.Negative impacts (Retention & Adherence) 3.Resources availability (Man, Money) 4.Feasibility & Sustainability 5.Prioritization 6.Equity and ethics How can BIG Data answer these questions ?

PWHA Cascade Source: AIDS Epidemic Model (AEM), NHSO, SSO, CSMBS, GF, and Thai GPO Status Reported number HIV+ currently alive (Estimated)459,509 (100%) HIV+ currently access to treatment246,049 (54%) HIV+ not accessed to treatment (if treat for all)213,460 (46%) never HIV+ never registered to National registry133,781 (63%) HIV+ ever registered to National registry79,679 (37%) Lost of follow up during pre-ART (CD4 > 350) 37,292 (47%) Lost of follow up during receiving ART 42,387 (53%) Only 54% of PWHA can access to ART Only 54% of PWHA can access to ART 46% cannot access to ART 46% cannot access to ART Among who cannot access to ART, 37% have been registered but lost during follow up Among who cannot access to ART, 37% have been registered but lost during follow up 47% - loss during pre-ART 47% - loss during pre-ART 53% - loss during receiving ART 53% - loss during receiving ART

Proportion of CD4 at Diagnosis and ART Initiation ( ) CD4 at newly HIV+ diagnosisCD4 at ART Initiation Nearly half of new HIV+ had very low CD4 (less than 100) at the time of diagnosis and ART initiation These findings demonstrated late access to HIV care services, thus reflecting the performance of HCT program Performance of HCT Program need to be improved Median CD4

23,510 (6%) (71%) (82%) (43%) (56%) (38%) Cascade Accessing and Retention to Care-ART, (2007 – 2013), NAP Monitoring System, NHSO Data source: NAP Database, National Health Security Office

Effectiveness of ART Program (2012) Data source: National Health Security Office Total Registration to care and treatment services = 326,271 Pre-ART Retention rate 87% Retention rate 31% Receiving ART In pre-ART, loss to follow up occurs 3 times higher than ART group A number of PWA who are eligible for ART didn’t receive treatment In ART group, 70% of who retained to ART has viral load suppression Quality of care in ART program need to be improved 70%

Using Projecting Model to Forecast ART Service Demands Data input from NAP is required in order to calculate service demand from Projecting Model Estimated number of PLHA receiving ART

ART Service Demand Forecasting (UHC Schemes only) Within next 5 years (2019), work load will increase ~ 20 – 50 %

ART Budget Forecasting ( ) Scenario Additional budget needed (drugs+lab) Total program budget rising from Any CD4 + Current HCT Any CD4 + 25% increasing HCT Any CD4 + 50% increasing HCT Any CD % increasing HCT ART Unit Cost (Drugs + Lab) = 352 USD/pt/yr, not include cost of HCT, capacity building, operation) Unit = million USD Additional budget needed from baseline scenario In the next 5 years, additional budget need for drugs and lab would be 18 – 55 mUSD To end AIDS in the next 10 years, Thailand would spend totally of 400 mUSD in addition to baseline scenario

National Health Security Office 17 CD4 < 350 CD CD4 > 500Total # Estimated PWHIV308,37974,76076,371459,510 Known HIV status (Above water)246,0498,9716,109261,129 HIV status unknown (Under water)62,33065,78970,262198,381(43%) % coverage80%12%8% 57% CD4 < 350 CD4 = CD4 > 500 Known HIV status unknown Issue on Equity and Priority % of PWHIV do not know their HIV status. One-third of which urgently need ART (<350). Barriers stop them from accessing to health services. already accessed DO NOTexisting barriers Initiating ART at any CD4 just only benefit for people who are already accessed to services, but DO NOT solve the existing barriers in the inaccessible group. In resources limited setting, who should we considered a PRIORITY ?

Conclusion TasP could reduce new HIV infection and has showed some potential in ending AIDS To implement this intervention, some critical issues should be seriously considered Health infra-structure strengthening (including human resources) for: – Extensive HCT scaling up esp. MARPs – Effective quality improvement to increase early access and retention to ART Long term budget availability including domestic and external resources

Acknowledgement National Health Security Office (NHSO) Thailand MoPH-US CDC Collaboration (TUC) Bureau of AIDS, TB and STIs, MoPH All ART centers under UHC network